AllianceBernstein
KYMR icon

AllianceBernstein’s Kymera Therapeutics KYMR Stock Holding History

AllianceBernstein’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.8M Buy
981,521
+93,486
+11% +$8.03M 0.03% 463
2026
Q1 		$69.1M Sell
888,035
-64,030
-7% -$5.07M 0.02% 496
2025
Q4 		$74.1M Buy
952,065
+903,296
+1,852% +$61M 0.02% 509
2025
Q3 		$2.76M Buy
48,769
+1,729
+4% +$78K ﹤0.01% 1821
2025
Q2 		$2.05M Buy
47,040
+2,050
+5% +$70.6K ﹤0.01% 1919
2025
Q1 		$1.23M Sell
44,990
-43,256
-49% -$1.58M ﹤0.01% 2135
2024
Q4 		$3.55M Sell
88,246
-36,368
-29% -$1.64M ﹤0.01% 1658
2024
Q3 		$5.9M Buy
124,614
+30,946
+33% +$1.37M ﹤0.01% 1451
2024
Q2 		$2.8M Sell
93,668
-8,435
-8% -$292K ﹤0.01% 1767
2024
Q1 		$4.1M Buy
102,103
+63,703
+166% +$2.28M ﹤0.01% 1549
2023
Q4 		$978K Buy
38,400
+400
+1% +$7.15K ﹤0.01% 2282
2023
Q3 		$528K Hold
38,000
– – ﹤0.01% 2546
2023
Q2 		$874K Hold
38,000
– – ﹤0.01% 2347
2023
Q1 		$1.13M Hold
38,000
– – ﹤0.01% 2169
2022
Q4 		$948K Hold
38,000
– – ﹤0.01% 2312
2022
Q3 		$827K Hold
38,000
– – ﹤0.01% 2398
2022
Q2 		$748K Sell
38,000
-23,614
-38% -$552K ﹤0.01% 2498
2022
Q1 		$2.61M Buy
61,614
+24,914
+68% +$1.05M ﹤0.01% 1936
2021
Q4 		$2.33M Hold
36,700
– – ﹤0.01% 2044
2021
Q3 		$2.16M Sell
36,700
-900
-2% -$52.2K ﹤0.01% 2125
2021
Q2 		$1.82M Buy
37,600
+26,800
+248% +$1.16M ﹤0.01% 2250
2021
Q1 		$420K Buy
10,800
+4,000
+59% +$241K ﹤0.01% 2744
2020
Q4 		$422K Buy
+6,800
New +$332K ﹤0.01% 2663

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

AllianceBernstein's KYMR Position: Q2 2026 in Review

AllianceBernstein increased its Kymera Therapeutics (KYMR) stake by 11% in Q2 2026, buying an estimated $8.03M and bringing the position to 981,521 shares worth $81.8M. The position accounts for 0.03% of the portfolio, ranked #463.

AllianceBernstein first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • AllianceBernstein held 981,521 shares of Kymera Therapeutics worth $81.8M as of Q2 2026.
  • AllianceBernstein bought 93,486 Kymera Therapeutics shares in Q2 2026, an estimated $8.03M.
  • Kymera Therapeutics made up 0.03% of AllianceBernstein's portfolio in Q2 2026, its #463 holding.
  • AllianceBernstein first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.